EUCTR2004-002218-13-IT
Active, not recruiting
Not Applicable
A phase III, multicenter, randomized, open, comparative study to evaluate if the addition of r-hLH (Luveris) ti FSH from day 8 of ovarian stimulation is able to decrease total FSH dose and to improve cycle outcome in infertile women undergoing ART, who required high FSH dose in a previous cycle.
INDUSTRIA FARMACEUTICA SERONO0 sites250 target enrollmentSeptember 20, 2005
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Reduction of the FSH dose needed to obtain/retrieve each oocyte after administration of Luveris to FSH at day 8 of ovarian stimulation.
- Sponsor
- INDUSTRIA FARMACEUTICA SERONO
- Enrollment
- 250
- Status
- Active, not recruiting
- Last Updated
- 14 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) no
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Not Applicable
Study to compare the reactogenicity and evaluate the safety and immunogenicity of GSK Biologicals combined hepatitis A / hepatitis B vaccine administered according to a 0, 6 month schedule versus Twinrix™ Junior administered according to a 0, 1, 6 month schedule in healthy children between 1 to 11 years old.Vaccination of healthy children from 1 to 11 years old against HepatitisTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2015-001515-12-Outside-EU/EEAGlaxoSmithKline Biologicals511
Active, not recruiting
Not Applicable
A study for evaluation of immunogenicity and reactogenicity of Fluarix/Influsplit SSW 2012/2013 in people aged 18 years and above.EUCTR2012-000789-39-DEGlaxoSmithKline Biologicals
Active, not recruiting
Phase 3
Study to assess the efficacy and safety of alpelisib in combination with olaparib in participants with platinum-resistant or refractory gBRCAnm HGSOCOvarian CancerJPRN-jRCT2031210106Suzuki Kazuyuki30
Completed
Phase 3
A study of Alcaftadine 0.25% w/v and Ketorolac Tromethamine 0.4% w/v Eye Drops for the treatment of Subjects with Ocular Itching associated with Allergic ConjunctivitisHealth Condition 1: null- Ocular Itching associated with Allergic conjunctivitisHealth Condition 2: H108- Other conjunctivitisCTRI/2018/09/015810Ajanta Pharma Ltd222
Completed
Phase 3
A Clinical study to check the effect and safety of Olopatadine Hydrochloride Ophthalmic Solution 0.7% w/v compared with Olopatadine Hydrochloride Ophthalmic Solution 0.2% w/v in patients suffering with ocular itching associated with allergic conjunctivitis.Health Condition 1: null- Ocular Itching associated with Allergic ConjunctivitisHealth Condition 2: H108- Other conjunctivitisCTRI/2018/05/013693Ajanta Pharma Ltd219